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Summary The level of galactosyltransferase activity was measured in the serum of 220 patients with a variety
of solid tumours. There was a significantly greater proportion of patients with elevated galactosyltransferase
in the group with metastatic disease (43%) than for the group with localised disease (16%). Galactosyl-
transferase was elevated in 69% of patients with liver metastasis compared to 32% of patients with metastatic
disease at sites other than liver and this difference was also significant. High resolution agarose
isoelectricfocusing was used to determine the 'isoenzyme' pattern of serum galactosyltransferase of 6 patients
with liver metastasis and 2 patients with primary hepatoma and these were compared to those of 6 patients
with similar primary tumours without liver involvement. There were no qualitative differences in the patterns
from the two groups. The average peak height for each of the 19 peaks of activity identified was generally
higher in the group with liver involvement, except for those peaks known to contain little or no attached sialic
acid. Liver involvement appears not to contribute in any specific way to the altered pattern of serum
galactosyltransferase often seen in patients with solid tumours. The tumour rather than the liver is therefore
the most likely source of these alterations.
The tumour marker potential of galactosyltrans-
ferase has been the subject of many reports (Weiser
& Wilson, 1981) and it is now well established that
the serum level of this enzyme is often elevated in
patients with solid tumours (Kim et al., 1972; Capel
et al., 1982; Motoki et al., 1981; Chatterjee et al.,
1979; Paone et al., 1980). Using high resolution
agarose isoelectricfocusing (Davey et al., 1983) to
separate serum galactosyltransferase, we showed
that 30 of 38 (79%) patients with solid tumours
had quantitative alterations in their galactosyl-
transferase activity profiles, even though only 26%
had elevated serum levels (Davey et al., 1984).
Although different activity patterns were obtained
for various patients, neither the clinical implications
nor the biological reasons for these cancer-
associated alterations in total enzyme activity or the
pattern of activity are known.
Evidence suggesting the tumour may be the
source of the additional galactosyltransferase in
serum is based on reports that the enzyme levels are
often higher in the tumour than in the normal
uninvolved tissue (Kessel et al., 1977; Kijimoto-
Ochiai et al., 1981; Mookerjea & Schimmer, 1975;
Bhattacharya et al., 1976) and that many
transformed cell lines release large amounts of
galactosyltransferase into the culture supernatant
(Klohs et al., 1981; Whitehead et al., 1979; Liu et
al., 1982).
Another possibility is that the liver may release
additional galactosyltransferase since Ip and Dao
(1977) reported that there was an increase in the
galactosyltransferase level in the liver as well as in
the serum of rats with localised mammary tumours.
Qian et al. (1984) reported that patients with
either primary hepatoma or liver metastasis had
two serum forms of galactosyltransferase resolved
by column isoelectricfocusing, compared to three
forms found in normal healthy control subjects and
patients with benign liver disease. This finding that
liver involvement can cause an alteration in the
activity pattern of serum galactosyltransferase
suggests the liver may be the source of these
changes.
The quantitative changes in the serum pattern we
reported (Davey et al., 1984) did not take into
account whether patients had liver involvement. We
therefore undertook this study to determine to what
extent neoplastic liver involvement alters the serum
galactosyltransferase pattern as detected by high
resolution agarose isoelectricfocusing. An under-
standing of the effect of liver involvement on the
serum pattern of galactosyltransferase may also
help to determine whether the liver is the source of
the additional enzyme often found in the serum of
cancer patients.
Materials and methods
Serum samples were collected from cancer patients
with and without liver metastasis before their
treatment commenced and these were stored from 1
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to 16 months at -70°C until the analysis. Th " loss
of galactosyltransferase activity is 10% per 12
months under these conditions. The level of
galactosyltransferase in the serum was measured as
previously described (Davey et al., 1983) using
UDP-Galactose-3H as substrate and ovalbumin as
the acceptor. The coefficient of variation for this
assay was always <8% and the interassay
coefficients of variation were always < 10%.
To determine the galactosyltransferase isoenzyme
pattern, 0.02ml serum was applied to a high
resolution agarose isoelectricfocusing gel with a pH
range of 4 to 6.5. After focusing, the gel was cut
into 2mm slices and the galactosyltransferase
activity of each slice was measured (Davey et al.,
1983). The reproducibility of this method was
similar to that reported by Davey et al. (1983) with
variation between runs in peak heights of <20%.
Results
Table I shows the incidence of elevated galactosyl-
transferase in the pretreatment serum of patients
for the various sites of primary tumour and the
extent of metastatic disease. The upper limit of
normal (mean+2 s.d.) of the healthy control group
was 47.2nmol galactose transferred ml-' serum
h-1. Seventy-seven of the 220 patients (35%) had
elevated galactosyltransferase levels.
Table I The incidence of elevated galactosyltransferase in
pretreatment serum from patients with solid tumours.
Proportion ofpatients with elevated
serum galactosyltransferase levels
Site of Non-liver Liver
primary Local metastasis metastasis Total
Breast 1/11 2/16 6/7 9/34
Gastrointestinal 2/11 8/26 11/21 21/58
Lung 4/11 7/20 4/6 15/37
Genitourinary 0/5 12/29 5/5 17/39
Head and neck 1/17 0/8 0/0 1/25
Unknown 0/0 4/7 5/6 9/13
Other 2/8 3/6 0/0 5/14
Total 10/63 36/112 31/45 77/220
Patients in the group whose site of primary was
unknown had a higher proportion with elevated
galactosyltransferase (69%) than the total patient
group. All other site of primary groups had similar
proportions of patients with elevated galactosyl-
transferase as the total patient group (Chi-square
test).
Galactosyltransferase levels were elevated in 43%
of patients with metastatic disease compared to
only 16% of patients with local disease (Figure 1)
and this difference was highly significant
(P<0.0005 by Chi-square test). There was also a
highly significant difference (P<0.0001 by Chi-
square test) between the 67% of patients with
elevated galactosyltransferase who had liver
metastasis and the 32% with high levels who had
metastatic involvement at sites other than liver.
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Figure 1 Distribution of serum galactosyltransferase
activity for patients with solid tumours. The
percentage of patients in each group with elevated
galactosyltransferase activity is given. N =Normal
controls, L=Localised disease, M =Metastatic disease,
Mo =Metastasis at sites other than liver, Mh =Hepatic
metastasis.
The galactosyltransferase 'isoenzyme' patterns in
the pretreatment serum of 6 patients with liver
metastasis and 2 with primary hepatoma were
compared to those of 6 patients having similar
primary tumours but with no liver involvement
(Figure 2). Although there was some variation in
the number of peaks identified in each profile, this
always involved minor species and there were no
consistent qualitative differences in the profiles of
the two groups. However there were substantial
quantitative differences in the profiles, with as
much variation within the two patient groups as
between them. A typical activity profile of a normal
healthy control is also included in Figure 2.
The quantitative differences in the galactosyl-
transferase activity patterns between patients with
and without liver involvement were further analysed
by comparing the mean peak heights of each of the
19 peaks (Figure 3). The mean peak heights were
generally higher in the group with liver involvement
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Figure 2 Serum galactosyltransferase activity profiles of patients with and without liver involvement. The
corresponding serum levels of galactosyltransferase activity in nmol Galml-' serum h-V is given in the top
right of each profile. B =Breast cancer, S =Stomach cancer, C/R =Colorectal cancer, H =Hepatoma,
-Mh =with liver metastasis, N =Normal heatlhy control.
but there were no significant differences between
the two groups for any of the peaks (t test).
The area under each activity profile in Figure 2
was not always proportional to the total serum
activity. This may be due to inhibitors oftotal serum
activity which are separated from the enzyme during
isoelectricfocusing. Inhibitors ofgalactosyltransferase
in the serum of cancer patients has been reported
previously (Podolsky & Weiser, 1979).
Discussion
The patient group in Figure 1 had a variety of
primary tumour sites, including breast, lung,
genitourinary and gastrointestinal tract. We have
shown that those patients with metastasis have
higher pretreatment levels of serum galactosyl-
transferase than patients with localised tumours.
This is similar to the reports of Paone et al. (1980)
and Ip and Dao (1978) for patients with breast
cancer but differs from the findings of Capel et al.
(1982), who showed that although the serum level
of galactosyltransferase of patients with metastasis
was generally higher than in those with localised
prostatic, breast, lung or gastrointestinal tumours,
the difference between the two groups was not
significant.
Patients with liver involvement have higher
galactosyltransferase levels than those with meta-
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Figure 3 The mean peak heights from the galactosyltransferase activity profiles of patients with (open) and
without (shaded) liver involvement. The standard deviation has been included.
static disease at sites other than liver (Figure 1).
Motoki et al. (1981) reported the same trend but
found that the galactosyltransferase level was not
significantly higher in patients with liver
involvement.
Liu et al. (1982) showed that both hepatoma cells
and cells cultured from normal human liver (Chang
cells) released large amounts of galactosyltrans-
ferase into their supernatants. Galactosyltransferase
released from the hepatoma cells differed from that
of the Chang cells since a greater proportion bound
to Concanavalin A. Recently this group (Qian et al.,
1984) used column isoelectricfocusing to fractionate
serum galactosyltransferase, and reported that
patients with neoplastic liver disease had only two
forms with isoelectric points of 4.75 and 4.95
compared to the three forms (4.80, 4.95 and 5.1)
found in normal healthy serum and in patients
with non-neoplastic liver disease. We were unable to
confirm this report since we found no qualitative
difference between the galactosyltransferase acti-
vity profiles of cancer patients with and without
liver involvement (Figures 2, 3). The serum in our
study was stored frozen whereas Qian et al. (1984)
used fresh serum. This cannot be the reason for
the difference in results since the pattern obtained
by high resolution agarose isoelectricfocusing is not
altered by freezing or freeze-thawing (Davey et al.,
1983).
The most likely reason for the difference in
results is that the agarose isoelectricfocusing method
has greater resolving power than column isoelectric-
focusing used by Qian et al. (1984). Figure 3 shows
that the proportion of activity in the forms with a
pl above 5.16 is less in the patient group with liver
involvement. Using column isoelectricfocusing this
may appear as a loss when it is actually a
quantitative reduction.
The 5.41, 5.69 and 5.98 forms of galactosyltrans-
ferase contain little or no attached sialic acid
(Davey et al., 1983) and these forms are rarely
elevated in patients with solid tumours (Davey et
al., 1984). It is interesting to note that these are the
forms that are proportionally reduced in cancer
patients with liver involvement.
We reported that patients with solid tumours
often had altered serum galactosyltransferase
patterns (Davey et al., 1984). The results presented
in Figure 2 and 3 show that liver involvement
seems not to contribute to these alterations in any
specific way but rather it may cause a general
increase in the levels of most forms. These findings
are therefore more consistent with the tumour,
rather than the liver, being the source of the altered
serum enzyme pattern. This is further substantiated
by the fact that patients with liver involvement
usually have a greater tumour burden than those
without liver involvement and this would account
for the observed general increase in the levels of
most galactosyltransferase forms in patients with
liver involvement.
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